(0.28%) 5 114.47 points
(0.38%) 38 385 points
(0.36%) 15 985 points
(-1.63%) $82.48
(4.94%) $2.02
(0.27%) $2 353.60
(0.21%) $27.59
(4.19%) $960.75
(-0.20%) $0.933
(-0.34%) $10.99
(-0.53%) $0.796
(1.70%) $93.44
Live Chart Being Loaded With Signals
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA...
Stats | |
---|---|
今日成交量 | 245 298 |
平均成交量 | 564 056 |
市值 | 0.00 |
EPS | $0 ( 2023-03-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0560 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-01-19 | Bate Kenneth | Sell | 375 | Common Stock |
2023-01-19 | Bate Kenneth | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Evnin Anthony B | Sell | 22 500 | Stock Option (Right to Buy) |
2023-01-19 | Ledell Jebediah | Sell | 27 702 | Stock Option (Right to Buy) |
2023-01-19 | Ferraresso Michael | Sell | 220 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
46.33 |
Last 96 transactions |
Buy: 43 011 518 | Sell: 9 966 796 |
音量 相关性
Aveo Pharmaceuticals Inc 相关性 - 货币/商品
Aveo Pharmaceuticals Inc 财务报表
Annual | 2021 |
营收: | $38.87M |
毛利润: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2021 |
营收: | $38.87M |
毛利润: | $34.14M (87.81 %) |
EPS: | $-2.49 |
FY | 2020 |
营收: | $6.02M |
毛利润: | $4.77M (79.32 %) |
EPS: | $-1.660 |
FY | 2019 |
营收: | $28.80M |
毛利润: | $0.00 (0.00 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Aveo Pharmaceuticals Inc
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。